Literature DB >> 16307825

Prospective hospital-wide studies of 505 patients with nosocomial bacteraemia in 1997 and 2002.

Z Jerassy1, A M Yinnon, S Mazouz-Cohen, S Benenson, Y Schlesinger, B Rudensky, D Raveh.   

Abstract

We conducted surveys in 1997 and 2002 to determine the rate, underlying sources and outcome of nosocomial bacteraemia. Blood culture results were reviewed daily. All patients with positive cultures drawn >or=48 h after hospitalization were included in the study and their charts were reviewed. The underlying source of infection was determined by pre-defined clinical and/or microbiological criteria. Patients were followed until discharge or death. In 1997 and 2002, 851 and 857 patient-unique cases of bacteraemia were diagnosed, respectively, excluding contaminants; of these, 228 (27%) and 277 (32%) cases, respectively, were hospital acquired (P<0.05). The overall rate decreased from 7.5 to 7.0 per 1,000 admissions (P<0.001). The sources of bacteraemia in 1997 and 2002, respectively, were: intravascular catheters (36% and 27%, P<0.05), urinary tract (8% and 15%, P<0.05), respiratory tract (5% and 13%, P<0.01) and surgical sites (14% and 4%, P<0.001). In one-third of patients, the source of bacteraemia could not be determined. Only 52% and 54%, respectively, of these patients were discharged alive (difference was not significant). In 1997, Staphylococcus aureus was the most frequent isolate (26%), followed by coagulase-negative Staphylococcus (13%) and Klebsiella pneumoniae (11%). By 2002, the incidence of S. aureus had fallen to 11% (P<0.001), acinetobacter was the single most frequently isolated organism (increased from 6% to 17%) (P<0.001). In-hospital mortality associated with acinetobacter bacteraemia (57%) was significantly higher than that for other organisms (31-43%) (P<0.05). In conclusion, prospective surveys of nosocomial bacteraemias provide valuable information, facilitating the pursuit of successful interventions.

Entities:  

Mesh:

Year:  2005        PMID: 16307825     DOI: 10.1016/j.jhin.2005.07.007

Source DB:  PubMed          Journal:  J Hosp Infect        ISSN: 0195-6701            Impact factor:   3.926


  9 in total

1.  The K1 capsular polysaccharide of Acinetobacter baumannii strain 307-0294 is a major virulence factor.

Authors:  Thomas A Russo; Nicole R Luke; Janet M Beanan; Ruth Olson; Shauna L Sauberan; Ulrike MacDonald; L Wayne Schultz; Timothy C Umland; Anthony A Campagnari
Journal:  Infect Immun       Date:  2010-07-19       Impact factor: 3.441

Review 2.  Specific and Selective Bacteriophages in the Fight against Multidrug-resistant Acinetobacter baumannii.

Authors:  Natalia Bagińska; Anna Pichlak; Andrzej Górski; Ewa Jończyk-Matysiak
Journal:  Virol Sin       Date:  2019-05-15       Impact factor: 4.327

3.  In vivo and in vitro activity of the siderophore monosulfactam BAL30072 against Acinetobacter baumannii.

Authors:  Thomas A Russo; Malcolm G P Page; Janet M Beanan; Ruth Olson; Andrea M Hujer; Kristine M Hujer; Michael Jacobs; Saralee Bajaksouzian; Andrea Endimiani; Robert A Bonomo
Journal:  J Antimicrob Chemother       Date:  2011-02-13       Impact factor: 5.790

Review 4.  Acinetobacter baumannii: emergence of a successful pathogen.

Authors:  Anton Y Peleg; Harald Seifert; David L Paterson
Journal:  Clin Microbiol Rev       Date:  2008-07       Impact factor: 26.132

5.  Epidemiology of bacteremia episodes in a single center: increase in Gram-negative isolates, antibiotics resistance, and patient age.

Authors:  D Marchaim; R Zaidenstein; T Lazarovitch; Y Karpuch; T Ziv; M Weinberger
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2008-06-05       Impact factor: 3.267

6.  Persistence of antibiotic resistance plasmids in bacterial biofilms.

Authors:  Benjamin J Ridenhour; Genevieve A Metzger; Michael France; Karol Gliniewicz; Jack Millstein; Larry J Forney; Eva M Top
Journal:  Evol Appl       Date:  2017-05-08       Impact factor: 5.183

7.  Risk factors for mortality in patients with carbapenem-resistant Acinetobacter baumannii bacteremia: impact of appropriate antimicrobial therapy.

Authors:  Youn Jeong Kim; Sang Il Kim; Kyung-Wook Hong; Yang Ree Kim; Yeon Joon Park; Moon-Won Kang
Journal:  J Korean Med Sci       Date:  2012-04-25       Impact factor: 2.153

8.  Acinetobacter spp. are associated with a higher mortality in intensive care patients with bacteremia: a survival analysis.

Authors:  Aline C Q Leão; Paulo R Menezes; Maura S Oliveira; Anna S Levin
Journal:  BMC Infect Dis       Date:  2016-08-09       Impact factor: 3.090

9.  Association of capsular types with carbapenem resistance, disease severity, and mortality in Acinetobacter baumannii.

Authors:  Yu-Chia Hsieh; Shi-Heng Wang; Yi-Yin Chen; Tzu-Lung Lin; Shian-Sen Shie; Ching-Tai Huang; Chen-Hsiang Lee; Yi-Ching Chen; Tran Lam Tu Quyen; Yi-Jiun Pan
Journal:  Emerg Microbes Infect       Date:  2020-12       Impact factor: 7.163

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.